Research Highlight |
Featured
-
-
-
-
Review Article |
Towards personalized treatment for early stage HER2-positive breast cancer
HER2-targeted therapy has greatly improved the outcomes of patients with HER2-positive breast cancer, with a range of agents now approved or in late-stage clinical development. In the era of precision medicine, efforts are being made to further improve patient outcomes by personalizing HER2-targeted treatment regimens, primarily though escalation or de-escalation of therapy according to the disease biology. In this Review, the authors provide an overview of the current landscape of HER2-targeted therapy and discuss the evidence supporting such tailored therapeutic strategies.
- Kristina Goutsouliak
- , Jamunarani Veeraraghavan
- & Rachel Schiff
-
-
News & Views |
Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma
The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.
- Alvaro J. Alencar
- & Craig H. Moskowitz
-
-
Review Article |
The changing therapeutic landscape of head and neck cancer
The authors of this Review discuss treatments currently available for patients with head and neck squamous cell carcinomas (focusing in those of the oral cavity, oropharynx, hypopharynx and larynx). Advances in surgical and non-surgical approaches (mainly combinations of radiotherapy and chemotherapy) are discussed, including the first immunotherapeutic agents approved for these malignancies.
- John D. Cramer
- , Barbara Burtness
- & Robert L. Ferris
-
-
-
Research Highlight |
Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma
- David Killock
-
-
-
Review Article |
Optimizing the outcomes of pancreatic cancer surgery
Successful surgical resection offers patients with pancreatic cancer the best chance of survival. However, many patients do not have surgically resectable disease. In this Review, the authors describe recent improvements in pancreatic cancer surgery, which have increased survival and also enabled more patients to undergo surgery.
- Oliver Strobel
- , John Neoptolemos
- & Markus W. Büchler
-
-
Research Highlight |
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss
- David Killock
-
-
Review Article |
The multiple myelomas — current concepts in cytogenetic classification and therapy
The multiple myelomas (MMs) are heterogeneous malignancies that are nearly always associated with chromosomal abnormalities, which can be considered either primary or secondary abnormalities. The classification of MM according to the underlying primary cytogenetic abnormality might enable the development of better treatment strategies. The authors describe treatment approaches that consider the current standard of care for patients with MM along with recommendations for certain subgroups of patients.
- Shaji K. Kumar
- & S. Vincent Rajkumar
-
In Brief |
Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease
- David Killock
-
Editorial |
A call for pragmatism in cancer research
-
-
-
-
Research Highlight |
Daratumumab proves effective in patients with newly diagnosed multiple myeloma
- Peter Sidaway
-
-
Year in Review |
Practice-changing updates in the adjuvant and metastatic setting
2017 has been full of new discoveries that will influence the treatment of colorectal cancer. In the adjuvant setting, 3 months of chemotherapy might now be considered a new standard of care. Various other new treatments and promising biomarkers have also become available that will improve survival outcomes and the quality of life of many patients with metastatic disease.
- Alberto Puccini
- & Heinz-Josef Lenz
-
-
-
-
News & Views |
Integrating PROs into the clinic — overall survival benefit or not, it's worth the trouble
In 2016, results of an important randomized trial demonstrated that patients undergoing chemotherapy who reported symptoms electronically have a better quality of life than those receiving usual care. Now, a significant survival improvement for patients in the experimental arm of this study has been reported. The emphasis of this survival benefit is 'culturally' positive, promoting the adoption of patient-reported outcomes in clinical practice.
- Elisa Sperti
- & Massimo Di Maio
-
-
News & Views |
Where are we now with the treatment of multiple myeloma?
The current standard-of-care therapy for patients with multiple myeloma is autologous stem-cell transplantation; however, whether this approach should be enhanced or displaced by triplet combination therapy is the subject of ongoing debate. We discuss the latest trial that has attempted to address this question and the impact of transplantation and triplet therapy assessment and surrogate end points in future trial design.
- Gareth J. Morgan
- & Leo Rasche
-
-
-
Research Highlight |
New chemoradiation standard for elderly patients with glioblastoma
- Lisa Hutchinson
-
-
-
-
-
Opinion |
The changing landscape of clinical trial and approval processes in China
The expansion of research and development of anticancer drugs in China has resulted in considerable delays in the approval of both clinical trials of novel agents, and the marketing approval of these agents once tested. In this Perspective, the authors describe the measures taken by the Chinese FDA to address these challenges in a rapidly developing research environment.
- Qing Zhou
- , Xiao-Yuan Chen
- & Yi-Long Wu
-
-
Correspondence |
First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm
- Chiara Cremolini
- , Carlotta Antoniotti
- & Alfredo Falcone
-
-
-
-
-
News & Views |
Improved diagnosis, therapy and outcomes for patients with CUP
Molecular cancer-classifier assays enable the diagnosis of a single cancer type for most patients with cancer of unknown primary (CUP), thus opening the door to the administration of site-specific therapies. Herein, I discuss how such therapies can improve the survival of patients with CUP, and the resulting paradigm shift towards tissue-of-origin diagnostics and treatments that is now becoming the standard of care for this patient population.
- F. Anthony Greco
-
Review Article |
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
In this Review, the authors describe the developing therapeutic landscape for patients with muscle-invasive bladder cancer. In particular, the data supporting the use of neoadjuvant cisplatin-based chemotherapy as a standard of care, the potential impact of genomic profiling on treatment approaches, and the emerging importance of immunotherapy are discussed.
- Samuel A. Funt
- & Jonathan E. Rosenberg
-
Opinion |
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
Autophagy is fundamental to cellular homeostasis and also has a central role in the development and progression of cancer. However, autophagy is also required for optimal immune system function, including the development of an anticancer immune response. In this Perspective, the authors present the available preclinical and clinical evidence that autophagy might enhance the effectiveness of both immunogenic chemotherapy and radiotherapy, as opposed to the general view of inhibition of autophagy as an antitumour strategy.
- Lorenzo Galluzzi
- , José Manuel Bravo-San Pedro
- & Guido Kroemer
-